Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi-database, non-interventional post-authorization safety study

Diabetes, Obesity and Metabolism

Volumn 19, Issue 10, 2017, Pages 1473-1478

  Williams, Rachael ^a,b   de Vries, Frank ^b,c   Kothny, Wolfgang ^d   Serban, Carmen ^d   Lopez Leon, Sandra ^d   Chu, Changan ^d,e   Schlienger, Raymond ^d  

^a Clinical Practice Research Datalink   (United Kingdom)

^b UTRECHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NOVARTIS PHARMA AG   (Switzerland)

^e SANOFI   (France)

Author keywords

cardiovascular disease; DPP 4 inhibitor; observational study; type 2 diabetes; vildagliptin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; METFORMIN PLUS VILDAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN; ADAMANTANE; NITRILE; PYRROLIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; ADVERSE DRUG REACTION; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; AGED; ANALOGS AND DERIVATIVES; CARDIOTOXICITY; CHEMICALLY INDUCED; COMPLICATION; DIABETIC CARDIOMYOPATHY; EUROPE; FACTUAL DATABASE; MIDDLE AGED; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

ADAMANTANE; ADULT; AGED; CARDIOTOXICITY; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRILES; PYRROLIDINES; RETROSPECTIVE STUDIES;

EID: 85029800004     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12951     Document Type: Article

References (14)

1. International Diabetes Federation. IDF Diabetes. 7th ed. Brussels, Belgium: International Diabetes Federation; 2015. http://www.diabetesatlas.org. Accessed April 18, 2016.
2. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed April 19, 2016.
3. Committee for Medicinal Products for Human Use (CHMP). Concept paper on the need for revision of the note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus. 2008. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003182.pdf. Accessed April 19, 2016.
4. Ahuja V, Chou CH. Novel therapeutics for diabetes: uptake, usage trends, and comparative effectiveness. Curr Diab Rep. 2016;16(6):47.
5. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-1326.
6. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232-242.
7. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327-1335.
8. McInnes G, Evans M, Del Prato S, et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diabetes Obes Metab. 2015;17(11):1085-1092.
9. Krum H, Lukashevich V, Bolli GB, Kozlovski P, Kothny W, Ponikowski P. No significant difference in risk of heart failure hospitalization with vildagliptin in diabetic patients with systolic chronic heart failure: VIVIDD Study. Diabetes. 2014;63(suppl 1):A265.
10. Wijnands JM, van Durme CM, Driessen JH, et al. Individuals with type 2 diabetes mellitus are at an increased risk of gout but this is not due to diabetes: a population-based cohort study. Medicine (Baltimore). 2015;94(32):e1358.
11. Becher H, Kostev K, Schröder-Bernhardi D. Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther. 2009;47(10):617-626.
12. Gaist D, Sørensen HT, Hallas J. The Danish prescription registries. Dan Med Bull. 1997;44(4):445-458.
13. The National Board of Health and Welfare, Sweden. http://www.socialstyrelsen.se/register/halsodataregister/patientregistret/inenglish. Accessed July 15, 2016.
14. Mehrotra DV, Heyse JF. Use of the false discovery rate for evaluating clinical safety data. Stat Methods Med Res. 2004;13(3):227-238.